Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer.

A-R Hanauske; M Lahn; L C Musib; K Weigang-Köhler; E Yilmaz; T Graefe; B Kuenen; D Thornton; P McNealy; G Giaccone

doi:10.1093/annonc/mdp049

Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer.

A-R Hanauske
, M Lahn
, L C Musib
, K Weigang-Köhler
, E Yilmaz
, T Graefe
, B Kuenen
, D Thornton
, P McNealy
, G Giaccone

Universitätsklinik für Innere Medizin 5 - Onkologie und Hämatologie

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

22 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	156-175
Fachzeitschrift	ANNALS OF ONCOLOGY
Jahrgang	20
Ausgabenummer	9
DOIs	https://doi.org/10.1093/annonc/mdp049
Publikationsstatus	Veröffentlicht - 2009

Zugriff auf Dokument

10.1093/annonc/mdp049

Dieses zitieren

Hanauske, A.-R., Lahn, M., Musib, L. C., Weigang-Köhler, K., Yilmaz, E., Graefe, T., Kuenen, B., Thornton, D., McNealy, P., & Giaccone, G. (2009). Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. ANNALS OF ONCOLOGY , 20(9), 156-175. https://doi.org/10.1093/annonc/mdp049

Hanauske, A-R ; Lahn, M ; Musib, L C et al. / Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. in: ANNALS OF ONCOLOGY 2009 ; Jahrgang 20, Nr. 9. S. 156-175.

@article{e7aba33fc50b46498f1c8edf4b220a94,

title = "Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer.",

keywords = "KINASE-C-BETA, CELL LUNG-CANCER, INHIBITOR ENZASTAURIN, IN-VITRO, MULTITARGETED ANTIFOLATE, SELECTIVE INHIBITOR, DOSE-ESCALATION, ONCOLOGY TRIALS, THYROID-CANCER, SOLID TUMORS",

author = "A-R Hanauske and M Lahn and Musib, \{L C\} and K Weigang-K{\"o}hler and E Yilmaz and T Graefe and B Kuenen and D Thornton and P McNealy and G Giaccone",

year = "2009",

doi = "10.1093/annonc/mdp049",

language = "English",

volume = "20",

pages = "156--175",

journal = "ANNALS OF ONCOLOGY ",

issn = "0923-7534",

publisher = "Elsevier ",

number = "9",

}

Hanauske, A-R, Lahn, M, Musib, LC, Weigang-Köhler, K, Yilmaz, E, Graefe, T, Kuenen, B, Thornton, D, McNealy, P & Giaccone, G 2009, 'Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer.', ANNALS OF ONCOLOGY , Jg. 20, Nr. 9, S. 156-175. https://doi.org/10.1093/annonc/mdp049

Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. / Hanauske, A-R; Lahn, M; Musib, L C et al.
in: ANNALS OF ONCOLOGY , Jahrgang 20, Nr. 9, 2009, S. 156-175.

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

TY - JOUR

T1 - Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer.

AU - Hanauske, A-R

AU - Lahn, M

AU - Musib, L C

AU - Weigang-Köhler, K

AU - Yilmaz, E

AU - Graefe, T

AU - Kuenen, B

AU - Thornton, D

AU - McNealy, P

AU - Giaccone, G

PY - 2009

Y1 - 2009

KW - KINASE-C-BETA

KW - CELL LUNG-CANCER

KW - INHIBITOR ENZASTAURIN

KW - IN-VITRO

KW - MULTITARGETED ANTIFOLATE

KW - SELECTIVE INHIBITOR

KW - DOSE-ESCALATION

KW - ONCOLOGY TRIALS

KW - THYROID-CANCER

KW - SOLID TUMORS

U2 - 10.1093/annonc/mdp049

DO - 10.1093/annonc/mdp049

M3 - Original Article

C2 - 19487488

SN - 0923-7534

VL - 20

SP - 156

EP - 175

JO - ANNALS OF ONCOLOGY

JF - ANNALS OF ONCOLOGY

IS - 9

ER -

Hanauske AR, Lahn M, Musib LC, Weigang-Köhler K, Yilmaz E, Graefe T et al. Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. ANNALS OF ONCOLOGY . 2009;20(9):156-175. doi: 10.1093/annonc/mdp049